| Literature DB >> 29872469 |
Filippo Maffezzoni1, Teresa Porcelli2, Ioannis Karamouzis2, Eugenia Quiros-Roldan3, Francesco Castelli4, Gherardo Mazziotti5, Andrea Giustina6.
Abstract
The advent of highly active anti-retroviral therapy (HAART) has significantly improved the survival of human immunodeficiency virus (HIV)-infected patients transforming the HIV infection from a fatal illness into a manageable chronic disease. As the number of older HIV-infected individuals increases, several ageing-related co-morbidities including osteopenia/osteoporosis and fractures have emerged. Patients exposed to HIV infection and its treatment may develop fragility fractures with potential significant impact on quality of life and survival. However, the awareness of HIV-related skeletal fragility is still relatively low and most HIV-infected patients are not investigated for osteoporosis and treated with anti-osteoporotic drugs in daily clinical practice. This article reviews the literature data on osteoporosis and osteopenia in HIV infection, focusing on the pathophysiological, clinical and therapeutic aspects of fragility fractures.Entities:
Keywords: HAART; HIV; fractures; osteoporosis; retroviral drugs
Year: 2014 PMID: 29872469 PMCID: PMC5983102 DOI: 10.17925/EE.2014.10.01.79
Source DB: PubMed Journal: Eur Endocrinol ISSN: 1758-3772